Search Results

33 results

  1. CORESTA Meeting, Smoke Science/Product Technology, 2021, Online, NAM 00

    Advancing new alternative methods for tobacco harm reduction

    LEE K.M.(1); BELL S.(2)
    (1) Altria Client Services LLC, Richmond, VA, U.S.A.; (2) Integrated Laboratory Systems (ILS), Morrisville, NC, U.S.A.
    New approach methodologies (NAMs) represent in vitro and in silico or computational methodologies, an emerging set of chemical safety assessment tools without needing additional in vivo animal testing. This virtual symposium introduces the current...
  2. CORESTA Meeting, Smoke Science/Product Technology, 2021, Online, ST 38

    In vitro to in vivo extrapolation (IVIVE) for evaluating exposure and health impacts of e-vapor products using ingredient and mixture in vitro data

    ZHANG Jingjie(1); CHANG X.(2); HINES D.(2); BELL S.(2); LEE K.M.(1)
    (1) Altria Client Services LLC, Richmond, VA, U.S.A.; (2) Integrated Laboratory Systems (ILS), RTP, NC, U.S.A.
    In Vitro to In Vivo Extrapolation (IVIVE) uses reverse dosimetry to translate in vitro bioactivity data to clinically relevant exposure metrics. This study applies the IVIVE approach to e-vapor products using reported in vitro cytotoxicity data of...
  3. CORESTA Meeting, Smoke Science/Product Technology, 2021, Online, ST 50

    In vivo genotoxicity testing of aerosols generated from JUUL ENDS products

    LALONDE G.(1); ZHANG Jingjie(2); JALIGAMA S.(3); GUPTA A.(3); PSURNY E.(3); LEE K.M.(2); DOSHI U.(2); YAO J.(1)
    (1) JUUL Labs, Inc., San Francisco, CA, U.S.A.; (2) Altria Client Services, LLC, Richmond, VA, U.S.A. (a Service Provider to Juul Labs, Inc.); (3) Battelle Memorial Institute, West Jefferson, OH, U.S.A.
    We evaluated the in vivo genotoxicity potential of aerosols generated from two commercial nicotine electronic delivery systems (ENDS) products, P1 and P2, with a combined micronucleus (MN) and comet study design based on OECD TG 474 and...
  4. CORESTA Meeting, Smoke Science/Product Technology, 2021, Online, ST 57

    Nonclinical toxicity assessment of oral tobacco-derived nicotine products: I. Framework

    ZHANG M.; SMITH C.; MORGAN R.; DOSHI U.; KUMAR A.; LEE K.M.
    Altria Client Services LLC, Richmond, VA, U.S.A.
    There is an increasing acknowledgement of a broad "continuum of risk" among tobacco products, with combustible cigarettes at the highest end and non-combustible products toward the lower end of health risk. The oral tobacco-derived nicotine (OTDN)...
  5. CORESTA Meeting, Smoke Science/Product Technology, 2021, Online, ST 58

    Nonclinical toxicity assessment of oral tobacco-derived nicotine products: II. Ingredient evaluation

    MORGAN R.; AWOYEMI O.; ANDERSON C.; ZHANG M.; LEE K.M.
    Altria Client Services LLC, Richmond, VA, U.S.A.
    The oral tobacco-derived nicotine (OTDN) product category is one of the fastest growing tobacco product segments in the United States offering alternative nicotine products that do not contain tobacco. A rigorous nonclinical toxicological assessment...
  6. CORESTA Meeting, Smoke Science/Product Technology, 2021, Online, ST 59

    Nonclinical toxicity assessment of oral tobacco-derived nicotine products: III. Extraction and test material characterization

    SMITH C.; ZHANG M.; HURST T.; DOSHI U.; KUMAR A.; MORGAN R.; LEE K.M.
    Altria Client Services LLC, Richmond, VA, U.S.A.
    The oral tobacco-derived nicotine (OTDN) product category is one of the fastest growing tobacco product segments in the United States, offering alternative nicotine products that do not contain tobacco. A rigorous nonclinical toxicological assessment...
  7. CORESTA Meeting, Smoke Science/Product Technology, 2021, Online, ST 60

    Nonclinical toxicity assessment of oral tobacco-derived nicotine products: IV. In vitro regulatory testing

    DOSHI U.; SMITH C.; KUMAR A.; MORGAN R.; ZHANG M.; LEE K.M.
    Altria Client Services LLC, Richmond, VA, U.S.A.
    The oral tobacco-derived nicotine (OTDN) product category is one of fastest growing tobacco product segments in the United States offering alternative nicotine products that do not contain tobacco. A rigorous, nonclinical, toxicological assessment,...
  8. CORESTA Meeting, Smoke Science/Product Technology, 2021, Online, ST 61

    Nonclinical toxicity assessment of oral tobacco-derived nicotine products: V. In vitro mechanistic assays using human gingival fibroblasts

    KUMAR A.; DOSHI U.; SMITH C.; MORGAN R.; ZHANG M.; LEE K.M.
    Altria Client Services LLC, Richmond, VA, U.S.A.
    The oral tobacco-derived nicotine (OTDN) product category is one of the fastest growing tobacco product segments in the United States, offering alternative nicotine products that do not contain tobacco. A rigorous nonclinical toxicity assessment is...
  9. CORESTA Congress, Online, 2020, Smoke Science/Product Technology Groups, STPOST 16

    Comparison of in vitro cytotoxicity and genotoxicity of condensates derived from electronic-cigarettes and reference combustible cigarette

    DOSHI U.; GARDNER W.; LEE K.M.
    Altria Client Services LLC, Richmond, VA, U.S.A.
    In recent years, electronic nicotine delivery systems (ENDS) including electronic cigarettes (e-cigarettes) have emerged as potential reduced-risk alternatives to conventional cigarettes for adult smokers. The U.S. Food and Drug Administration (FDA),...
  10. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 13

    Importance of e-liquid preparation and stability characterization for a combinatorial safety assessment approach of flavors in e-liquids

    GLABASNIA A.(1); DIANA P.(1); SMITH C.(2); MILLER J.H.(2); BIASIOLI M.(1); FRAUENDORFER F.(1); SCIUSCIO D.(1); MARTIN E.(1); POSPISIL P.(1); GUY P.(1); VANSCHEEUWIJCK P.(1); HOENG J.(1); KUMAR A.(2); LEE K.M.(2)
    (1) PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland; (2) Altria Client Services LLC, Richmond, VA, U.S.A.
    Numerous flavorings are generally recognized as safe for use in food, but there is limited information available to evaluate their potential toxicity by inhalation. Consequently, gaining information on individual flavor safety levels is of...